BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-1984. [PMID: 9869669 DOI: 10.1056/nejm199812313392704] [Cited by in Crossref: 969] [Cited by in F6Publishing: 242] [Article Influence: 42.1] [Reference Citation Analysis]
Number Citing Articles
1 Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014;8:142-149. [PMID: 24210755 DOI: 10.1016/j.molonc.2013.10.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
2 Biersack B. Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs. Noncoding RNA Res 2017;2:1-17. [PMID: 30159416 DOI: 10.1016/j.ncrna.2016.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Fang H, Chen J, Lin L, Liu F, Tian H, Chen X. A Strategy of Killing Three Birds with One Stone for Cancer Therapy through Regulating the Tumor Microenvironment by H 2 O 2 -Responsive Gene Delivery System. ACS Appl Mater Interfaces 2019;11:47785-97. [DOI: 10.1021/acsami.9b18144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
4 Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 2009;1:145-65. [PMID: 21789119 DOI: 10.1177/1758834009347323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. Br J Surg 2017;104:1816-28. [PMID: 28944954 DOI: 10.1002/bjs.10627] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
6 Donlon NE, Sheppard A, Davern M, O'Connell F, Phelan JJ, Power R, Nugent T, Dinneen K, Aird J, Greene J, Nevins Selvadurai P, Bhardwaj A, Foley EK, Ravi N, Donohoe CL, Reynolds JV, Lysaght J, O'Sullivan J, Dunne MR. Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinoma-An Emerging Role for Chemokines. Cancers (Basel) 2020;12:E3356. [PMID: 33202734 DOI: 10.3390/cancers12113356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Koyanagi K, Kanamori K, Ninomiya Y, Yatabe K, Higuchi T, Yamamoto M, Tajima K, Ozawa S. Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan. Cancers (Basel) 2020;13:E51. [PMID: 33375499 DOI: 10.3390/cancers13010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Krasna MJ. Stage-specific therapy for cancer of the oesophagus: a new 'cancer of the elderly'. Drugs Aging 2009;26:185-94. [PMID: 19358615 DOI: 10.2165/00002512-200926030-00001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Cáncer de esófago. Medicina Clínica 2008;130:423-8. [DOI: 10.1157/13117853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Patel N, Foley KG, Powell AG, Wheat JR, Chan D, Fielding P, Roberts SA, Lewis WG. Propensity score analysis of 18-FDG PET/CT-enhanced staging in patients undergoing surgery for esophageal cancer. Eur J Nucl Med Mol Imaging 2019;46:801-9. [PMID: 30116837 DOI: 10.1007/s00259-018-4118-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Shin WS, Kwon J, Lee HW, Kang MC, Na HW, Lee ST, Park JH. Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma. Cancer Sci. 2013;104:1120-1126. [PMID: 23663482 DOI: 10.1111/cas.12194] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
12 Tsuchikawa T, Ikeda H, Cho Y, Miyamoto M, Shichinohe T, Hirano S, Kondo S. Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol. 2011;164:50-56. [PMID: 21352198 DOI: 10.1111/j.1365-2249.2010.04311.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
13 Zhang W, Pang Q, Zhang X, Yan C, Wang Q, Yang J, Yu S, Liu X, Pan Y, Yuan Z, Wang P, Xiao Z. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Sci 2017;108:590-7. [PMID: 28192623 DOI: 10.1111/cas.13197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
14 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Jonsson L, Hedner C, Gaber A, Korkocic D, Nodin B, Uhlén M, Eberhard J, Jirström K. High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomark Res 2014;2:11. [PMID: 24963396 DOI: 10.1186/2050-7771-2-11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
16 Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci 2016;107:726-33. [PMID: 27015293 DOI: 10.1111/cas.12938] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
17 Lin MW, Yang PW, Lee JM. Translational research in thoracic surgery-the National Taiwan University Hospital experience. J Thorac Dis 2016;8:S642-7. [PMID: 27651941 DOI: 10.21037/jtd.2016.07.95] [Reference Citation Analysis]
18 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Shen LY, Fan MY, Dong B, Yan WP, Chen KN. Increased HOXC6 expression predicts chemotherapy sensitivity in patients with esophageal squamous cell carcinoma. Oncol Lett 2017;14:4835-40. [PMID: 29085488 DOI: 10.3892/ol.2017.6772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89:2045-2050. [PMID: 14647136 DOI: 10.1038/sj.bjc.6601364] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 4.2] [Reference Citation Analysis]
21 Luketich JD, Alvelo-Rivera M, Buenaventura PO, Christie NA, McCaughan JS, Litle VR, Schauer PR, Close JM, Fernando HC. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg. 2003;238:486-94; discussion 494-5. [PMID: 14530720 DOI: 10.1097/01.sla.0000089858.40725.68] [Cited by in Crossref: 184] [Cited by in F6Publishing: 329] [Article Influence: 9.7] [Reference Citation Analysis]
22 Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, Ricardi U. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Med Oncol 2017;34:40. [PMID: 28176241 DOI: 10.1007/s12032-017-0898-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Fietkau R. [No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma]. Strahlenther Onkol 1999;175:251-2. [PMID: 10356618 DOI: 10.1007/BF02742406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Shah RD, Cassano AD, Neifeld JP. Neoadjuvant therapy for esophageal cancer. World J Gastrointest Oncol 2014; 6(10): 403-406 [PMID: 25320656 DOI: 10.4251/wjgo.v6.i10.403] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
25 Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013; 19(48): 9282-9293 [PMID: 24409055 DOI: 10.3748/wjg.v19.i48.9282] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
26 Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg 2015;149:538-47. [PMID: 25454907 DOI: 10.1016/j.jtcvs.2014.10.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
27 Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, Zhong Q, Wen ZS. High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget 2015;6:6850-61. [PMID: 25760075 DOI: 10.18632/oncotarget.3190] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
28 Chen HY, Ma XM, Ye M, Hou YL, Xie HY, Bai YR. Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma. J Radiat Res 2014;55:940-7. [PMID: 24914102 DOI: 10.1093/jrr/rru031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
29 Park JS, Van der Wall H, Kennedy C, Falk GL. Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated? World J Gastrointest Surg 2021; 13(10): 1235-1244 [PMID: 34754391 DOI: 10.4240/wjgs.v13.i10.1235] [Reference Citation Analysis]
30 Siewert JR, Stein HJ, von Rahden BH. Multimodal treatment of gastrointestinal tract tumors: consequences for surgery. World J Surg. 2005;29:940-948. [PMID: 15988623 DOI: 10.1007/s00268-005-0010-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
31 DeCesaris CM, Berger M, Choi JI, Carr SR, Burrows WM, Regine WF, Simone CB 2nd, Molitoris JK. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. J Gastrointest Oncol 2020;11:663-73. [PMID: 32953150 DOI: 10.21037/jgo-20-205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Li C, Lin JW, Yeh HL, Chuang CY, Chen CC. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. Sci Rep 2021;11:11626. [PMID: 34078965 DOI: 10.1038/s41598-021-90753-y] [Reference Citation Analysis]
33 Rawat S, Kumar G, Kakria A, Sharma MK, Chauhan D. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointest Cancer 2013;44:277-84. [PMID: 23389866 DOI: 10.1007/s12029-013-9477-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
34 Ishido K, Higuchi K, Azuma M, Sasaki T, Tanabe S, Katada C, Yano T, Wada T, Koizumi W; Kitasato Digestive Disease & Oncology Group. Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002). Anticancer Drugs 2016;27:884-90. [PMID: 27254283 DOI: 10.1097/CAD.0000000000000385] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
35 Kong X, Gong S, Su L, Li C, Kong Y. Expression signatures and roles of MicroRNAs in human oesophageal adenocarcinomas. J Cell Mol Med. 2018;22:123-130. [PMID: 28799211 DOI: 10.1111/jcmm.13300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
36 Liu T, Ding S, Dang J, Wang H, Chen J, Li G. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol 2019;14:176. [PMID: 31619265 DOI: 10.1186/s13014-019-1388-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
37 Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol 2018;117:150-9. [PMID: 28833197 DOI: 10.1002/jso.24808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
38 Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 2012;82:1967-72. [PMID: 21507583 DOI: 10.1016/j.ijrobp.2011.01.043] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
39 van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006;94:1389-94. [PMID: 16670722 DOI: 10.1038/sj.bjc.6603134] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
40 Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2013;24:2844-9. [PMID: 23975663 DOI: 10.1093/annonc/mdt339] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
41 Wang Y, Wang Q, Zhang N, Ma H, Gu Y, Tang H, Xu Z, Gao Y. Identification of microRNAs as novel biomarkers for detecting esophageal squamous cell carcinoma in Asians: a meta-analysis. Tumour Biol. 2014;35:11595-11604. [PMID: 25135426 DOI: 10.1007/s13277-014-2350-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
42 Allum WH, Griffin SM, Watson A, Colin-Jones D; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland., British Society of Gastroenterology., British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut 2002;50 Suppl 5:v1-23. [PMID: 12049068 DOI: 10.1136/gut.50.90005.v1] [Cited by in F6Publishing: 49] [Reference Citation Analysis]
43 Cai W, Zhang J, Chen Y, Kong W, Huang Y, Huang J, Zhou L. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. Chin J Cancer 2017;36:47. [PMID: 28521783 DOI: 10.1186/s40880-017-0214-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Shih LH, Chen SW, Li SH. Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis. Sci Rep 2018;8:15073. [PMID: 30305678 DOI: 10.1038/s41598-018-33400-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Yoon HH, Lowe VJ, Cassivi SD, Romero Y. The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. Gastroenterol Clin North Am. 2009;38:105-120, ix. [PMID: 19327570 DOI: 10.1016/j.gtc.2009.01.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
47 Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxì A, Cammà C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30. [PMID: 15194636 DOI: 10.1136/gut.2003.025080] [Cited by in Crossref: 402] [Cited by in F6Publishing: 350] [Article Influence: 22.3] [Reference Citation Analysis]
48 Fujiwara Y, Lee S, Kishida S, Hashiba R, Gyobu K, Takemura M, Osugi H. Safety and feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy for esophageal cancer. Surg Today 2017;47:1356-60. [PMID: 28386749 DOI: 10.1007/s00595-017-1526-6] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
49 Patel AN, Preskitt JT, Kuhn JA, Hebeler RF, Wood RE, Urschel HC Jr. Surgical management of esophageal carcinoma. Proc (Bayl Univ Med Cent) 2003;16:280-4. [PMID: 16278698 DOI: 10.1080/08998280.2003.11927914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
50 Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230-244. [PMID: 23296250 DOI: 10.1038/nrgastro.2012.236] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
51 Heise JW, Heep H, Frieling T, Sarbia M, Hartmann KA, Röher HD. Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus. BMC Cancer. 2001;1:20. [PMID: 11737874 DOI: 10.1186/1471-2407-1-20] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
52 Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer. 2002;86:669-673. [PMID: 11875723 DOI: 10.1038/sj.bjc.6600166] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
53 Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci 2010;55:3304-14. [PMID: 20300841 DOI: 10.1007/s10620-010-1187-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
54 Sherman CA, Turrisi AT, Wallace MB, Reed CE. Locally advanced esophageal cancer. Curr Treat Options in Oncol 2002;3:475-85. [DOI: 10.1007/s11864-002-0067-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
55 Li B, Li J, Xu WW, Guan XY, Qin YR, Zhang LY, Law S, Tsao SW, Cheung AL. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget. 2014;5:11576-11587. [PMID: 25344912 DOI: 10.18632/oncotarget.2596] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
56 Anderegg MCJ, van der Sluis PC, Ruurda JP, Gisbertz SS, Hulshof MCCM, van Vulpen M, Mohammed NH, van Laarhoven HWM, Wiezer MJ, Los M, van Berge Henegouwen MI, van Hillegersberg R. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol. 2017;24:2282-2290. [PMID: 28424936 DOI: 10.1245/s10434-017-5827-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
57 Chen L, Liu X, Wang R, Wang Y, Zhang T, Gao D, Gao L. Minimally invasive esophagectomy for esophageal cancer according to the location of the tumor: Experience of 251 patients. Ann Med Surg (Lond) 2017;17:54-60. [PMID: 28417001 DOI: 10.1016/j.amsu.2017.03.038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
58 Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer 2011;117:925-30. [PMID: 20960497 DOI: 10.1002/cncr.25651] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
59 Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011;59:923-8. [PMID: 21295907 DOI: 10.1016/j.eururo.2011.01.034] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 8.6] [Reference Citation Analysis]
60 Tian X, Zhou JG, Zeng Z, Shuai T, Yi LJ, Ma L, Wang Y, Cao H, Song GM. Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. Med Oncol 2015;32:127. [PMID: 25794489 DOI: 10.1007/s12032-015-0521-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
61 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
62 Deans DA, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson-Brown S, Fearon KC. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer. 2009;100:63-69. [PMID: 19127266 DOI: 10.1038/sj.bjc.6604828] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 8.5] [Reference Citation Analysis]
63 Jia Y, Xiao Z, Jiang W, Chen G, Wang Z. Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy. Thorac Cancer 2017;8:592-9. [PMID: 28857475 DOI: 10.1111/1759-7714.12488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
64 Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA. Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925-1932. [PMID: 17680242 DOI: 10.1007/s00259-007-0521-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
65 Ammori BJ, Leeder PC, King RF, Barclay GR, Martin IG, Larvin M, McMahon MJ. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg 1999;3:252-62. [PMID: 10481118 DOI: 10.1016/s1091-255x(99)80067-5] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
66 Sun HB, Xing WQ, Liu XB, Zheng Y, Yang SJ, Wang ZF, Liu SL, Ba YF, Zhang RX, Liu BX, Fan CC, Chen PN, Liang GH, Yu YK, Liu Q, Wang HR, Li HM, Li ZX; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer 2020;20:303. [PMID: 32293362 DOI: 10.1186/s12885-020-06824-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
67 Diel A, Rodermann E, Kienzle HF, Meuthen D, Meuthen I. Curative treatment in a patient with gastric cancer stage IV: a case report. F1000Res 2012;1:34. [PMID: 24358825 DOI: 10.12688/f1000research.1-34.v1] [Reference Citation Analysis]
68 Zheng Y, Li Y, Liu X, Sun H, Wang Z, Zhang R. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) 2015;94:e1102. [PMID: 26166100 DOI: 10.1097/MD.0000000000001102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
69 Kelly MD, Walsh TN. Adjuvant treatment for resectable adenocarcinoma of the oesophagus. ANZ J Surg 2003;73:976-8. [PMID: 14632885 DOI: 10.1046/j.1445-2197.2003.t01-20-.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 2019;3:269-75. [PMID: 31131355 DOI: 10.1002/ags3.12243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
71 Zhang A, Deek MP, Kim S, Sayan M, Grann A, Wagman RT, Malhotra U, Hathout L, Biswal N, Zhang Y, Langenfeld J, Kennedy T, August DA, Jabbour SK. Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity. J Gastrointest Oncol 2019;10:513-22. [PMID: 31183202 DOI: 10.21037/jgo.2019.01.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Głuszek S, Kot M, Kotucha B, Stępień R, Kozieł D. Cancer of the oesophagus and gastroesophageal junction - a difficult clinical problem. Contemp Oncol (Pozn) 2014;18:349-54. [PMID: 25477759 DOI: 10.5114/wo.2014.43494] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
73 Shao Y, Chen D, Ye L, Wang XM, Wu QC, Zhang C. Survival benefit of perioperative chemotherapy for T1-3N0M0 stage esophageal cancer: a SEER database analysis. J Thorac Dis 2021;13:995-1004. [PMID: 33717572 DOI: 10.21037/jtd-20-2877] [Reference Citation Analysis]
74 Wan Z, Huang Z, Chen L. Survival predictors associated with signet ring cell carcinoma of the esophagus (SRCCE): A population-based retrospective cohort study. PLoS One 2017;12:e0181845. [PMID: 28746362 DOI: 10.1371/journal.pone.0181845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
75 McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol 2016;7:196-205. [PMID: 27034786 DOI: 10.3978/j.issn.2078-6891.2015.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials 2020;21:528. [PMID: 32546273 DOI: 10.1186/s13063-020-04334-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
77 Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol 2020;18:59. [PMID: 32199464 DOI: 10.1186/s12957-020-01830-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Vats HS, Banerjee TK, Resnick J, Khan Q. Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy. Clin Med Res 2006;4:184-8. [PMID: 16988098 DOI: 10.3121/cmr.4.3.184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2009;100:1725-1730. [PMID: 19436301 DOI: 10.1038/sj.bjc.6605070] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
80 Petri R, Zuccolo M, Brizzolari M, Rossit L, Rosignoli A, Durastante V, Petrin G, De Cecchis L, Sorrentino M. Minimally invasive esophagectomy: thoracoscopic esophageal mobilization for esophageal cancer with the patient in prone position. Surg Endosc 2012;26:1102-7. [PMID: 22042593 DOI: 10.1007/s00464-011-2006-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
81 Jensen AD, Grehn C, Nikoghosyan A, Thieke C, Krempien R, Huber PE, Debus J, Münter MW. Catch me if you can--the use of image guidance in the radiotherapy of an unusual case of esophageal cancer. Strahlenther Onkol. 2009;185:469-473. [PMID: 19714309 DOI: 10.1007/s00066-009-1935-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
82 Kumar P, Damle NA, Bal C. Role of F18-FDG PET/CT in the Staging and Restaging of Esophageal Cancer: A Comparison with CECT. Indian J Surg Oncol 2011;2:343-50. [PMID: 23204793 DOI: 10.1007/s13193-012-0128-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
83 Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med. 2004;2:35. [PMID: 15447788 DOI: 10.1186/1741-7015-2-35] [Cited by in Crossref: 156] [Cited by in F6Publishing: 130] [Article Influence: 8.7] [Reference Citation Analysis]
84 Li Q, Wu SG, Gao JM, Xu JJ, Hu LY, Xu T. Impact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes. J Radiat Res. 2013;54:307-314. [PMID: 23124992 DOI: 10.1093/jrr/rrs096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
85 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
86 Yang H, Fu JH. Progress in surgery-based multimodality therapy for resectable esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3471-3475 [DOI: 10.11569/wcjd.v20.i35.3471] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
87 Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, Ishimoto T, Baba Y, Mimori K, Baba H. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer. 2012;107:1233-1238. [PMID: 22955852 DOI: 10.1038/bjc.2012.396] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
88 Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Inoue M, Yamamura T. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep 2012;28:446-52. [PMID: 22664791 DOI: 10.3892/or.2012.1847] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
89 Zhang L, Li W, Lyu X, Song Y, Mao Y, Wang S, Huang J. Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Chin J Cancer Res 2017;29:149-55. [PMID: 28536494 DOI: 10.21147/j.issn.1000-9604.2017.02.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
90 Zhu W, Xing L, Yue J, Sun X, Sun X, Zhao H, Yu J. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012;85:e694-e701. [PMID: 22337686 DOI: 10.1259/bjr/29946900] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
91 Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, Gong L, Yu H, Yang H, Liu J, Lei T, Zhao Q, Mao W. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget 2016;7:50624-34. [PMID: 27244882 DOI: 10.18632/oncotarget.9562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
92 López Carrizosa MC, Samper Ots PM, Rodríguez Pérez A, Sotoca A, Sáez Garrido J, de Miguel MM. High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED). Clin Transl Oncol 2007;9:385-91. [DOI: 10.1007/s12094-007-0071-y] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
93 Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001;234:581-7. [PMID: 11685019 DOI: 10.1097/00000658-200111000-00001] [Cited by in Crossref: 156] [Cited by in F6Publishing: 133] [Article Influence: 7.4] [Reference Citation Analysis]
94 Kucharczuk JC, Kaiser LR. Radical lobectomy, esophagectomy, and mediastinal dissections for intrathoracic malignancy. Surg Oncol Clin N Am 2005;14:499-509, vi. [PMID: 15978426 DOI: 10.1016/j.soc.2005.05.001] [Reference Citation Analysis]
95 Chen CY, Wu D, Guo QQ, Wang H. Predictive factors for curative effect of preoperative chemotherapy in gastric cancer. Shijie Huaren Xiaohua Zazhi 2018; 26(30): 1758-1764 [DOI: 10.11569/wcjd.v26.i30.1758] [Reference Citation Analysis]
96 Huang Z, Li S, Yang X, Lu F, Huang M, Zhang S, Xiong Y, Zhang P, Si J, Ma Y, Yang Y. Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study. Cancer Manag Res 2019;11:1299-308. [PMID: 30799956 DOI: 10.2147/CMAR.S195355] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 De Giacomo T, Trentino P, Venuta F, Tsagkaropoulos S, Berloco PB, Diso D, Francioni F. Surgical treatment of esophageal carcinoma with curative intent: analysis of a single center experience. J Cardiothorac Surg 2013;8:52. [PMID: 23509872 DOI: 10.1186/1749-8090-8-52] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Wang J, Zhang YJ. Combination of concept and clinical practice - putting a high premium on neoadjuvant therapy for adenocarcinoma of the esophagogastric junction. Shijie Huaren Xiaohua Zazhi 2016; 24(21): 3223-3231 [DOI: 10.11569/wcjd.v24.i21.3223] [Reference Citation Analysis]
99 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
100 Abu Hejleh T, DeYoung BR, Engelman E, Deutsch JM, Zimmerman B, Halfdanarson TR, Berg DJ, Parekh KR, Lynch WR, Iannettoni MD, Bhatia S, Clamon G. Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World J Gastrointest Oncol 2012; 4(5): 103-108 [PMID: 22645633 DOI: 10.4251/wjgo.v4.i5.103] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
101 Wang Q, Zhu H, Xiao Z, Zhang W, Liu X, Zhang X, He J, Sun K, Wang L, Xu N. Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma. World J Surg Oncol 2013;11:278. [PMID: 24131756 DOI: 10.1186/1477-7819-11-278] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
102 Wang F, Zhang L, Xu Y, Xie Y, Li S. Comprehensive Analysis and Identification of Key Driver Genes for Distinguishing Between Esophageal Adenocarcinoma and Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:676156. [PMID: 34124063 DOI: 10.3389/fcell.2021.676156] [Reference Citation Analysis]
103 Hiraki Y, Kimura Y, Imano M, Kato H, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Makino T, Motoori M, Yamasaki M, Miyata H, Satou T, Satoh T, Furukawa H, Yano M, Doki Y, Yasuda T. Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma. Surg Today 2021;51:118-26. [PMID: 32596796 DOI: 10.1007/s00595-020-02059-7] [Reference Citation Analysis]
104 O'Neill JR, Kennedy ED, Save V, Langdale-Brown B, Wall L, Skipworth RJE, Paterson-Brown S. Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results. Int J Surg Oncol (N Y) 2017;2:e09. [PMID: 29177210 DOI: 10.1097/IJ9.0000000000000009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
105 Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CL, Wang WP, Li Z, Zhang LJ. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chin J Cancer. 2012;31:399-408. [PMID: 22572013 DOI: 10.5732/cjc.011.10406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
106 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Joseph R, Laks S, Meyers M, McRee AJ. Multidisciplinary Approach to the Management of Esophageal Malignancies. World J Surg 2017;41:1726-33. [PMID: 28361298 DOI: 10.1007/s00268-017-4009-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
108 Zhu Y, Liu M, Yun X, Wang D, Bai Y, Zhang G, Ji B, Jing C. Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer. Pathol Oncol Res 2017;23:657-63. [PMID: 28013492 DOI: 10.1007/s12253-016-0164-4] [Reference Citation Analysis]
109 Cox SJ, O'Cathail SM, Coles B, Crosby T, Mukherjee S. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Curr Oncol Rep 2017;19:7. [PMID: 28213876 DOI: 10.1007/s11912-017-0559-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Shimada A, Takeuchi H, Fukuda K, Suda K, Nakamura R, Wada N, Kawakubo H, Kitagawa Y. Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin. Esophagus 2018;15:209-16. [PMID: 30225740 DOI: 10.1007/s10388-018-0615-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Huang B, Chan EG, Pennathur A, Luketich JD, Zhang J. The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis. BMC Cancer 2021;21:1334. [PMID: 34911468 DOI: 10.1186/s12885-021-08896-0] [Reference Citation Analysis]
112 Meng MB, Jiang C, Tian LJ, Liu CL, Zhuang HQ, Chen ZJ, Song YC, Wang J, Pang QS, Zhao LJ, Yuan ZY, Wang P. Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2013;4:174-85. [PMID: 28920199 DOI: 10.1111/j.1759-7714.2012.00166.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
113 Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14(24): 3773-3780 [PMID: 18609699 DOI: 10.3748/wjg.14.3773] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
114 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
115 Sun L, Zhang H, Wu K. Esophageal Cancer: Current Options for Therapeutic Management. Gastrointest Tumors 2014;1:105-13. [PMID: 26674591 DOI: 10.1159/000362907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
116 Yanai H, Hirano A, Matsusaki K, Kawano T, Miura O, Yoshida T, Okita K, Shimizu N. Epstein-Barr virus association is rare in esophageal squamous cell carcinoma. Int J Gastrointest Cancer 2003;33:165-70. [PMID: 14716066 DOI: 10.1385/IJGC:33:2-3:165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
117 Butt J, Kandel G. Barrett esophagus: when to endoscope. Clin Endosc 2014;47:40-6. [PMID: 24570882 DOI: 10.5946/ce.2014.47.1.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
118 Kötz BS, Croft S, Ferry DR. Do delays between diagnosis and surgery in resectable oesophageal cancer affect survival? A study based on West Midlands cancer registration data. Br J Cancer 2006;95:835-40. [PMID: 16969353 DOI: 10.1038/sj.bjc.6603333] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
119 Zhang R, Han D, Li L, Luo W, Liu J, Qian L. EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway. Cancer Manag Res 2020;12:9539-49. [PMID: 33061640 DOI: 10.2147/CMAR.S261182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Chen YH, Lu HI, Wang YM, Lo CM, Chou SY, Huang CH, Shih LH, Chen SW, Li SH. The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. Oncotarget 2017;8:96190-202. [PMID: 29221198 DOI: 10.18632/oncotarget.21878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
121 Manzini G, Klotz U, Henne-Bruns D, Kremer M. Validity of studies suggesting preoperative chemotherapy for resectable thoracic esophageal cancer: A critical appraisal of randomized trials. World J Gastrointest Oncol 2020; 12(1): 113-123 [PMID: 31966919 DOI: 10.4251/wjgo.v12.i1.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Furukawa H, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation. Cancer Sci 2018;109:412-21. [PMID: 29168598 DOI: 10.1111/cas.13454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
123 Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy. Oncology 2010;79:363-9. [PMID: 21430405 DOI: 10.1159/000322498] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Ajani JA, Swisher SG. Three angels are dancing on the head of the esophageal cancer pin, but shouldn't we not topple one or two? Ann Surg Oncol 2014;21:2815-6. [PMID: 24756809 DOI: 10.1245/s10434-014-3695-5] [Reference Citation Analysis]
125 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
126 Lee H, Cho YS, Jung S, Kim H. Effect of nutritional risk at admission on the length of hospital stay and mortality in gastrointestinal cancer patients. Clin Nutr Res. 2013;2:12-18. [PMID: 23431114 DOI: 10.7762/cnr.2013.2.1.12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
127 Shen LY, Wang H, Dong B, Yan WP, Lin Y, Shi Q, Chen KN. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling. Oncotarget 2016;7:4531-41. [PMID: 26673820 DOI: 10.18632/oncotarget.6554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
128 Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ. Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci. 2005;20:618-623. [PMID: 16100454 DOI: 10.3346/jkms.2005.20.4.618] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
129 van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt EJ, Jager PL, Groen H, Plukker JT. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg. 2005;9:54-61. [PMID: 15623445 DOI: 10.1016/j.gassur.2004.09.055] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
130 Su X, Gao C, Feng X, Jiang M. miR-613 suppresses migration and invasion in esophageal squamous cell carcinoma via the targeting of G6PD. Exp Ther Med 2020;19:3081-9. [PMID: 32256796 DOI: 10.3892/etm.2020.8540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
131 Samson P, Robinson C, Bradley J, Lockhart AC, Puri V, Broderick S, Kreisel D, Krupnick AS, Patterson GA, Meyers B, Crabtree T. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients. J Thorac Oncol 2016;11:2227-37. [PMID: 27544058 DOI: 10.1016/j.jtho.2016.07.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
132 Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017;17:401. [PMID: 28578652 DOI: 10.1186/s12885-017-3386-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 15.4] [Reference Citation Analysis]
133 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
134 Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692. [PMID: 16244542 DOI: 10.1097/01.sla.0000186170.38348.7b] [Cited by in Crossref: 256] [Cited by in F6Publishing: 242] [Article Influence: 15.1] [Reference Citation Analysis]
135 Liu HL, Liu DQ. Retrospective study of photodynamic therapy for upper gastrointestinal cancers during past 25 years in China. Shijie Huaren Xiaohua Zazhi 2007; 15(2): 129-133 [DOI: 10.11569/wcjd.v15.i2.129] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
136 Petty RD, Samuel LM, Murray GI, MacDonald G, O'Kelly T, Loudon M, Binnie N, Aly E, McKinlay A, Wang W. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer. 2009;9:434. [PMID: 20003335 DOI: 10.1186/1471-2407-9-434] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
137 Yang PW, Hsu IJ, Chang CW, Wang YC, Hsieh CY, Shih KH, Wong LF, Shih NY, Hsieh MS, Hou MT, Lee JM. Visible-absorption spectroscopy as a biomarker to predict treatment response and prognosis of surgically resected esophageal cancer. Sci Rep 2016;6:33414. [PMID: 27624872 DOI: 10.1038/srep33414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
138 Kostakoglu L. FDG-PET Evaluation of Response to Treatment. PET Clin 2008;3:37-75. [PMID: 27158146 DOI: 10.1016/j.cpet.2008.09.001] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
139 Parzen JS, Chuong MD, Chang J, Rosen L, Urbanic J, Hartsell W, Tsai H, Sinesi C, Zeng J, Mishra M, Vargas C, Stevens C, Kabolizadeh P. Dosimetry and Acute Toxicity Profile of Patients With Esophageal Cancer Treated With Proton Beam Radiation Therapy: Outcomes From the Proton Collaborative Group REG001-09 Trial. Adv Radiat Oncol 2021;6:100751. [PMID: 34646969 DOI: 10.1016/j.adro.2021.100751] [Reference Citation Analysis]
140 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
141 Yang PW, Hsieh MS, Huang YC, Hsieh CY, Chiang TH, Lee JM. Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma. PLoS One 2014;9:e100326. [PMID: 24945674 DOI: 10.1371/journal.pone.0100326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
142 Seitz J, Duffaud F, Dahan L, Ries P, Ville E, Laugier R. Adénocarcinomes du bas œsophage et du cardia: quelle chimiothérapie ou chimioradiothérapie dans le traitement des récidives et des métastases? Cancer/Radiothérapie 2001;5:107s-12s. [DOI: 10.1016/s1278-3218(01)80015-9] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
143 Vos EL, Carr RA, Hsu M, Nakauchi M, Nobel T, Russo A, Barbetta A, Tan KS, Tang L, Ilson D, Ku GY, Wu AJ, Janjigian YY, Yoon SS, Bains MS, Jones DR, Coit D, Molena D, Strong VE. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. Br J Surg 2021;108:1332-40. [PMID: 34476473 DOI: 10.1093/bjs/znab228] [Reference Citation Analysis]
144 Schulze B, Bergis D, Balermpas P, Trojan J, Woeste G, Bechstein WO, Rödel C, Weiss C. Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncol Lett 2014;7:534-40. [PMID: 24396483 DOI: 10.3892/ol.2013.1709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
145 Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010;17:2184-92. [PMID: 20217248 DOI: 10.1245/s10434-010-0995-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
146 Collard JM, Otte JB, Fiasse R, Laterre PF, De Kock M, Longueville J, Glineur D, Romagnoli R, Reynaert M, Kestens PJ. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25-32. [PMID: 11420480 DOI: 10.1097/00000658-200107000-00005] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
147 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
148 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
149 Qian Q, Wu C, Chen J, Wang W. Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway. J Gastrointest Oncol 2020;11:337-55. [PMID: 32399275 DOI: 10.21037/jgo.2020.01.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713-8. [PMID: 20354452 DOI: 10.1097/JTO.0b013e3181d7776d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
151 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. [PMID: 32554564 DOI: 10.1136/bmj.m115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
152 Crosby T, Evans M, Gillies RS, Maynard ND. The management of a patient with an operable carcinoma of the oesophagus. Ann R Coll Surg Engl 2009;91:366-70. [PMID: 19622256 DOI: 10.1308/003588409X432428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
153 Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-530; discussion 530-531. [PMID: 11573045 DOI: 10.1097/00000658-200110000-00011] [Cited by in Crossref: 266] [Cited by in F6Publishing: 239] [Article Influence: 12.7] [Reference Citation Analysis]
154 Motoori M, Yano M, Yasuda T, Miyata H, Peng Y, Yamasaki M, Shiraishi O, Tanaka K, Ishikawa O, Shiozaki H, Doki Y. Early response to neoadjuvant chemotherapy in advanced esophageal cancer evaluated by computed tomography predicts the utility of a second cycle of chemotherapy. Mol Clin Oncol 2013;1:521-6. [PMID: 24649204 DOI: 10.3892/mco.2013.89] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
155 Blom D, Peters JH. Surgery, radiotherapy, and chemotherapy in carcinoma of the esophagus. Curr Opin Gastroenterol 2000;16:392-9. [PMID: 17031107 DOI: 10.1097/00001574-200007000-00017] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
156 Thirunavukarasu P, Gabriel E, Attwood K, Kukar M, Hochwald SN, Nurkin SJ. Nationwide analysis of short-term surgical outcomes of minimally invasive esophagectomy for malignancy. Int J Surg 2016;25:69-75. [PMID: 26602969 DOI: 10.1016/j.ijsu.2015.11.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
157 Zhou F, Zhu M, Wang M, Qiu L, Cheng L, Jia M, Xiang J, Wei Q. Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. J Transl Med. 2016;14:154. [PMID: 27246611 DOI: 10.1186/s12967-016-0903-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
158 Griffiths EA, Pritchard SA, Mapstone NP, Welch IM. Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist. World J Surg Oncol. 2006;4:82. [PMID: 17118194 DOI: 10.1186/1477-7819-4-82] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
159 Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, O'byrne K, Hollywood D, Muldoon C, Reynolds JV. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-9. [PMID: 17024121 DOI: 10.1038/sj.bjc.6603412] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 5.3] [Reference Citation Analysis]
160 Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc 2015;4:e79. [PMID: 26121676 DOI: 10.2196/resprot.4320] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
161 Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, Siersema PD, Dinjens WN, van Lanschot JJ, Tilanus HW, van der Gaast A. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011;11:181. [PMID: 21595951 DOI: 10.1186/1471-2407-11-181] [Cited by in Crossref: 96] [Cited by in F6Publishing: 87] [Article Influence: 8.7] [Reference Citation Analysis]
162 Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD. The Globalization of Cooperative Groups. Semin Oncol 2015;42:693-712. [PMID: 26433551 DOI: 10.1053/j.seminoncol.2015.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
163 Takiguchi S, Murakami K, Yanagimoto Y, Takata A, Miyazaki Y, Mori M, Doki Y. Clinical application of ghrelin in the field of surgery. Surg Today 2015;45:801-7. [PMID: 25366350 DOI: 10.1007/s00595-014-1040-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
164 Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003;27:1067-1074. [PMID: 12934159 DOI: 10.1007/s00268-003-7063-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
165 Park JC, Lee YC, Kim SK, Kim YJ, Shin SK, Lee SK, Kim H, Kim CB. Achalasia combined with esophageal cancer treated by concurrent chemoradiation therapy. Gut Liver 2009;3:329-33. [PMID: 20431771 DOI: 10.5009/gnl.2009.3.4.329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Makowiec F, Baier P, Kulemann B, Marjanovic G, Bronsert P, Zirlik K, Henke M, Hopt UT, Hoeppner J. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg 2013;17:1193-201. [PMID: 23636882 DOI: 10.1007/s11605-013-2212-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
167 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer 2019;10:1097-102. [PMID: 30854116 DOI: 10.7150/jca.29353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
168 Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg 2017;41:1719-25. [PMID: 28271259 DOI: 10.1007/s00268-017-3959-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
169 Donlon NE, Davern M, Sheppard A, Power R, O'Connell F, Heeran AB, King R, Hayes C, Bhardwaj A, Phelan JJ, Dunne MR, Ravi N, Donohoe CL, O'Sullivan J, Reynolds JV, Lysaght J. The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling. Cancers (Basel) 2021;13:4005. [PMID: 34439160 DOI: 10.3390/cancers13164005] [Reference Citation Analysis]
170 Jeromen A, Oblak I, Anderluh F, Velenik V, Vidmar MS, Ratoša I. Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. Radiol Oncol 2012;46:337-45. [PMID: 23412351 DOI: 10.2478/v10019-012-0049-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
171 Yanai H, Harada T, Okamoto T, Hirano A, Takeo N, Yoshida T, Okita K, Kawano T. Prognostic value and interobserver agreement of endoscopic ultrasonography for superficial squamous cell carcinoma of the esophagus: a prospective study. Int J Gastrointest Cancer. 2003;34:1-8. [PMID: 15235130 DOI: 10.1385/IJGC: 34: 1: 01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Lee IS, Ahn JY, Yook JH, Kim BS. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma. World J Surg Oncol 2017;15:28. [PMID: 28100248 DOI: 10.1186/s12957-016-1088-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
173 Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li H, Pan Y, Peng Y, Yao X, Liu P, Sun Y, Li B, Zhang Y. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis 2021;13:3518-28. [PMID: 34277047 DOI: 10.21037/jtd-21-340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Wang CP, Rogers MP, Bach G, Sujka J, Mhaskar R, DuCoin C. Safety comparison of minimally invasive abdomen-only esophagectomy versus minimally invasive Ivor Lewis esophagectomy: a retrospective cohort study. Surg Endosc 2021. [PMID: 33825009 DOI: 10.1007/s00464-021-08468-0] [Reference Citation Analysis]
175 Goel A, Shah SH, Selvakumar VP, Kahkasha S, Garg S, Pahuja AK, Dutta K, Batra U, Sharma SK, Doval DC, Kumar K. Radical Esophagectomy After Neoadjuvant Chemoradiation: Single Institutional Experience from Tertiary Cancer Centre in India. Indian J Surg Oncol 2015;6:207-12. [PMID: 27217665 DOI: 10.1007/s13193-015-0402-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
176 Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev 2017;8:CD010511. [PMID: 28829911 DOI: 10.1002/14651858.CD010511.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
177 Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg. 2017;6:167-174. [PMID: 28447006 DOI: 10.21037/acs.2017.03.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
178 Wang XB, Jiang XR, Yu XY, Wang L, He S, Feng FY, Guo LP, Jiang W, Lu SH. Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy. Cancer Sci. 2014;105:176-185. [PMID: 24383865 DOI: 10.1111/cas.12331] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
179 Garces CA, McAuliffe PF, Hochwald SN, Cance WG. Neoadjuvant therapy in the treatment of solid tumors. Curr Probl Surg 2006;43:457-551. [PMID: 16860653 DOI: 10.1067/j.cpsurg.2006.04.003] [Reference Citation Analysis]
180 Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015;CD001556. [PMID: 25988291 DOI: 10.1002/14651858.cd001556.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
181 Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, Haug A, Schoppmann SF, Ba-Ssalamah A. Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. Eur Radiol 2016;26:311-21. [PMID: 26040648 DOI: 10.1007/s00330-015-3860-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
182 Pan JY, Ajani JA, Gu J, Gong Y, Qin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 2012;118:4346-53. [PMID: 22213102 DOI: 10.1002/cncr.26581] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
183 Miyagaki H, Yamasaki M, Miyata H, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Fujiwara Y, Ishii H, Tanaka F, Mori M, Doki Y. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. Br J Cancer 2012;106:947-54. [PMID: 22333595 DOI: 10.1038/bjc.2012.35] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
184 van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008;8:21. [PMID: 19036143 DOI: 10.1186/1471-2482-8-21] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
185 Liu Y, Xie D, Li C, Lin C, Zhao J. Effects of neoadjuvant chemotherapy combined with radiotherapy in patients with advanced esophageal carcinoma. Oncol Lett 2017;14:2803-7. [PMID: 28927038 DOI: 10.3892/ol.2017.6515] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
186 Maingon P, Manfredi S. Adénocarcinome du bas œsophage et du cardia: prise en charge non chirurgicale. Cancer/Radiothérapie 2001;5:98s-106s. [DOI: 10.1016/s1278-3218(01)80014-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
187 Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246:1-8. [PMID: 17592282 DOI: 10.1097/01.sla.0000255563.65157.d2] [Cited by in Crossref: 151] [Cited by in F6Publishing: 136] [Article Influence: 10.1] [Reference Citation Analysis]
188 de Geus-Oei LF, Vriens D, Arens AI, Hutchings M, Oyen WJ. FDG-PET/CT based response-adapted treatment. Cancer Imaging 2012;12:324-35. [PMID: 23023063 DOI: 10.1102/1470-7330.2012.9006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
189 Shimoji H, Kinjo T, Karimata H, Nagahama M, Nishimaki T. Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors. Surg Today. 2013;Epub ahead of print. [PMID: 23963503 DOI: 10.1007/s00595-013-0700-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
190 Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 2007;7:189-94. [PMID: 18055293 DOI: 10.1102/1470-7330.2007.0027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
191 Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, Doki Y. Multimodal treatment for resectable esophageal cancer. Gen Thorac Cardiovasc Surg 2011;59:461-6. [PMID: 21751104 DOI: 10.1007/s11748-011-0780-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
192 Halliday BP, Skipworth RJ, Wall L, Phillips HA, Couper GW, de Beaux AC, Paterson-Brown S. Neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophago-gastric junction: a six-year experience. Int Semin Surg Oncol 2007;4:24. [PMID: 17937823 DOI: 10.1186/1477-7800-4-24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
193 Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007;245:707-16. [PMID: 17457163 DOI: 10.1097/01.sla.0000254367.15810.38] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 7.9] [Reference Citation Analysis]
194 Lin D, Ma L, Ye T, Pan Y, Shao L, Song Z, Jiang S, Chen H, Xiang J. Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma. J Thorac Dis 2017;9:318-26. [PMID: 28275480 DOI: 10.21037/jtd.2017.02.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
195 Ypsilantis PP, Siddique M, Sohn HM, Davies A, Cook G, Goh V, Montana G. Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. PLoS One. 2015;10:e0137036. [PMID: 26355298 DOI: 10.1371/journal.pone.0137036] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 12.6] [Reference Citation Analysis]
196 Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 2015;18:1-10. [PMID: 24638977 DOI: 10.1007/s10120-014-0356-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
197 Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Ann Thorac Cardiovasc Surg. 2017;23:1-11. [PMID: 28003586 DOI: 10.5761/atcs.ra.16-00162] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 13.8] [Reference Citation Analysis]
198 Lin JB, Hung LC, Cheng CY, Chien YA, Lee CH, Huang CC, Chou TW, Ko MH, Lai YC, Liu MT, Chang TH, Lee J, Chen YJ. Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy. Radiat Oncol 2019;14:85. [PMID: 31126307 DOI: 10.1186/s13014-019-1283-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Golabek T, Powroźnik J, Chłosta P, Dobruch J, Borówka A. The impact of nutrition in urogenital cancers. Arch Med Sci 2015;11:411-8. [PMID: 25995760 DOI: 10.5114/aoms.2015.50973] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
200 Martin RC 2nd, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg. 2002;235:803-813. [PMID: 12035036 DOI: 10.1097/00000658-200206000-00007] [Cited by in Crossref: 433] [Cited by in F6Publishing: 392] [Article Influence: 21.7] [Reference Citation Analysis]
201 Brücher BL, Kitajima M, Siewert JR. Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. Cancer Invest 2014;32:497-506. [PMID: 25250506 DOI: 10.3109/07357907.2014.958497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
202 Vošmik M, Kopecký J, John S, Kubeček O, Lochman P, Banni AM, Hruška L, Sirák I. Combined Therapy of Locally Advanced Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. Cancers (Basel) 2021;13:4591. [PMID: 34572818 DOI: 10.3390/cancers13184591] [Reference Citation Analysis]
203 Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol 2008;13:474-8. [PMID: 19093172 DOI: 10.1007/s10147-008-0853-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
204 Schölvinck D, Künzli H, Meijer S, Seldenrijk K, van Berge Henegouwen M, Bergman J, Weusten B. Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease. Surg Endosc. 2016;30:4102-4113. [PMID: 27357927 DOI: 10.1007/s00464-016-5071-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
205 Katsha A, Arras J, Soutto M, Belkhiri A, El-Rifai W. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. Mol Oncol. 2014;8:1419-1428. [PMID: 24953013 DOI: 10.1016/j.molonc.2014.05.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
206 Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist 2015;20:134-42. [PMID: 25561508 DOI: 10.1634/theoncologist.2014-0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
207 Wang WL, Chang WL, Yang HB, Wang YC, Chang IW, Lee CT, Chang CY, Lin JT, Sheu BS. Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma. Oncotarget 2016;7:71169-81. [PMID: 27036032 DOI: 10.18632/oncotarget.8460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
208 Sohda M, Saito H, Kuriyama K, Yoshida T, Kumakura Y, Honjyo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Sakai M, Miyazaki T, Fukuchi M, Kuwano H. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. In Vivo 2019;33:501-6. [PMID: 30804133 DOI: 10.21873/invivo.11502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
209 Verhoef C, van de Weyer R, Schaapveld M, Bastiaannet E, Plukker JT. Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists. Ann Surg Oncol 2007;14:1678-87. [PMID: 17294070 DOI: 10.1245/s10434-006-9333-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
210 Noronha V, Prabhash K, Joshi A, Patil VM, Talole S, Nakti D, Sahu A, Shah S, Ghosh-Laskar S, Patil PS, Mehta SA, Jambhekar N, Mahajan A, Purandare N. Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer. Oncol Res 2016;23:183-95. [PMID: 27053347 DOI: 10.3727/096504016X14537290676865] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
211 Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. Radiation field size and dose determine oncologic outcome in esophageal cancer. World J Surg Oncol 2016;14:263. [PMID: 27737673 DOI: 10.1186/s12957-016-1024-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
212 Gockel I, Sultanov FS, Domeyer M, Goenner U, Junginger T. Developments in esophageal surgery for adenocarcinoma: a comparison of two decades. BMC Cancer 2007;7:114. [PMID: 17603896 DOI: 10.1186/1471-2407-7-114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
213 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
214 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
215 Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 2017;6:501. [PMID: 28491289 DOI: 10.12688/f1000research.10794.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
216 Walsh GL, Mehran RJ. A Brief History of Thoracic Surgery at the University of Texas MD Anderson Cancer Center. Semin Thorac Cardiovasc Surg 2016;28:719-26. [PMID: 28285679 DOI: 10.1053/j.semtcvs.2016.08.016] [Reference Citation Analysis]
217 Meguid RA, Hooker CM, Taylor JT, Kleinberg LR, Cattaneo SM 2nd, Sussman MS, Yang SC, Heitmiller RF, Forastiere AA, Brock MV. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg 2009;138:1309-17. [PMID: 19931663 DOI: 10.1016/j.jtcvs.2009.07.069] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
218 Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376-84; discussion 384-5. [PMID: 12192324 DOI: 10.1097/01.sla.0000027925.23604.5c] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
219 Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 2011;13:157-67. [PMID: 21365188 DOI: 10.1007/s11912-011-0158-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
220 Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 2015;51:2545-52. [PMID: 26321501 DOI: 10.1016/j.ejca.2015.07.044] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
221 Depypere L, Thomas M, Moons J, Coosemans W, Lerut T, Prenen H, Haustermans K, Van Veer H, Nafteux P. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol 2019;17:89. [PMID: 31133018 DOI: 10.1186/s12957-019-1630-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
222 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Huang CH, Shih LH, Chen SW, Li SH. The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. PLoS One 2018;13:e0198800. [PMID: 29889869 DOI: 10.1371/journal.pone.0198800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
223 Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376-384; discussion 384-385. [PMID: 12192324 DOI: 10.1097/00000658-200209000-00014] [Cited by in Crossref: 181] [Cited by in F6Publishing: 165] [Article Influence: 9.1] [Reference Citation Analysis]
224 Chang EY, Li X, Jerosch-Herold M, Priest RA, Enestvedt CK, Xu J, Springer CS, Jobe BA. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg. 2008;12:166-175. [PMID: 17768665 DOI: 10.1007/s11605-007-0253-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
225 Wang XS, Ding XZ, Li XC, He Y, Kong DJ, Zhang L, Hu XC, Yang JQ, Zhao MQ, Gao SG, Lin TY, Li Y. A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically. Nanomedicine 2018;14:2103-14. [PMID: 30047470 DOI: 10.1016/j.nano.2018.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
226 Matuschek C, Bölke E, Zahra T, Knoefel WT, Peiper M, Budach W, Erhardt A, Scherer A, Baldus SE, Gerber PA, Buhren BA, Schauer M, Hoff NP, Gattermann N, Orth K. Trimodal therapy in squamous cell carcinoma of the esophagus. Eur J Med Res 2011;16:437-44. [PMID: 22024422 DOI: 10.1186/2047-783x-16-10-437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
227 Purwar P, Bambarkar S, Jiwnani S, Karimundackal G, Laskar SG, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg 2014;76:494-503. [PMID: 25614726 DOI: 10.1007/s12262-014-1163-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
228 Ilson DH. New developments in the treatment of esophageal cancer. Curr Oncol Rep 2002;4:213-21. [PMID: 11937011 DOI: 10.1007/s11912-002-0018-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
229 Capdevila L, Cros S, Ramirez JL, Sanz C, Carrato C, Romeo M, Etxaniz O, Hostalot C, Massuet A, Cuadra JL, Villà S, Balañà C. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. J Neurooncol 2014;117:77-84. [PMID: 24395350 DOI: 10.1007/s11060-013-1352-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
230 Liu HC, Hung SK, Huang CJ, Chen CC, Chen MJ, Chang CC, Tai CJ, Tzen CY, Lu LH, Chen YJ. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol 2005; 11(34): 5367-5372 [PMID: 16149148 DOI: 10.3748/wjg.v11.i34.5367] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
231 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
232 Shen S, Araujo JL, Altorki NK, Sonett JR, Rodriguez A, Sungur-Stasik K, Spinelli CF, Neugut AI, Abrams JA. Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients. Dis Esophagus 2017;30:1-7. [PMID: 28859366 DOI: 10.1093/dote/dox073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
233 Altorki NK, Christos P, Port JL, Lee PC, Mirza F, Spinelli C, Keresztes R, Beneck D, Paul S, Stiles BM, Zhang Y, Schrump DS. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol 2011;6:1121-7. [PMID: 21532508 DOI: 10.1097/JTO.0b013e31821529a9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
234 Onitilo AA, Stankowski-Drengler TJ, Shiyanbola O, Engel J, Tanimu S, Fagbemi SO, Li YH. Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC). Clin Med Res 2021;19:64-71. [PMID: 33789952 DOI: 10.3121/cmr.2021.1573] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, Resbeut M. Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction. Gastroenterol Res Pract 2015;2015:404203. [PMID: 26448741 DOI: 10.1155/2015/404203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
236 Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol. 2011;6:55. [PMID: 21615894 DOI: 10.1186/1748-717x-6-55] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
237 Hao W, Shen Y, Feng M, Wang H, Lin M, Fang Y, Tan L. Aspirin acts in esophageal cancer: a brief review. J Thorac Dis 2018;10:2490-7. [PMID: 29850157 DOI: 10.21037/jtd.2018.03.110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
238 Stahl M. [Combined preoperative radiochemotherapy in squamous cell carcinoma. The view of the medical oncologist]. Chirurg 2009;80:1006-10. [PMID: 19730797 DOI: 10.1007/s00104-009-1732-x] [Reference Citation Analysis]
239 Wood MD, Zaki BI, Gordon SR, Sutton JE Jr, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. J Thorac Oncol 2013;8:487-94. [PMID: 23370365 DOI: 10.1097/JTO.0b013e3182829bf3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
240 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Huang CC, Shih LH, Chen SW, Li SH. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. BMC Cancer 2018;18:837. [PMID: 30126380 DOI: 10.1186/s12885-018-4731-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
241 Agranovich A, McGahan CE, Gurjal A. Long-term survivorship of esophageal cancer patients treated with radical intent. Can J Gastroenterol 2008;22:393-8. [PMID: 18414715 DOI: 10.1155/2008/231878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
242 Baba Y, Watanabe M, Yoshida N, Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol 2014; 6(5): 121-128 [PMID: 24834142 DOI: 10.4251/wjgo.v6.i5.121] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
243 Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015;113:1427-1433. [PMID: 26554656 DOI: 10.1038/bjc.2015.354] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
244 Oh D, Kim JH. The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:160-7. [PMID: 32793446 DOI: 10.5090/kjtcs.2020.53.4.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
245 Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL. AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. J Gastrointest Oncol 2016;7:158-65. [PMID: 27034781 DOI: 10.3978/j.issn.2078-6891.2015.067] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
246 Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol 2011;28 Suppl 1:S152-61. [PMID: 20730572 DOI: 10.1007/s12032-010-9658-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
247 Sgourakis G, Gockel I, Radtke A, Musholt TJ, Timm S, Rink A, Tsiamis A, Karaliotas C, Lang H. Minimally invasive versus open esophagectomy: meta-analysis of outcomes. Dig Dis Sci. 2010;55:3031-3040. [PMID: 20186484 DOI: 10.1007/s10620-010-1153-1] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 9.1] [Reference Citation Analysis]
248 Hyodo I. Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. J Gastroenterol 2006;41:504-6. [PMID: 16799897 DOI: 10.1007/s00535-006-1835-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin SM, Phillips AW. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Ann Surg Oncol 2020;27:3182-92. [PMID: 32201923 DOI: 10.1245/s10434-020-08358-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer H, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2015;18:550-63. [DOI: 10.1007/s10120-014-0403-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
251 Otsubo D, Nakamura T, Yamamoto M, Kanaji S, Kanemitsu K, Yamashita K, Imanishi T, Oshikiri T, Sumi Y, Suzuki S, Kuroda D, Kakeji Y. Prone position in thoracoscopic esophagectomy improves postoperative oxygenation and reduces pulmonary complications. Surg Endosc 2017;31:1136-41. [PMID: 27387180 DOI: 10.1007/s00464-016-5081-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
252 Bowrey DJ, Evans MD, Clark GW. Impact of methicillin-resistant Staphylococcus aureus infection on outcome after esophagectomy. World J Surg 2007;31:326-31. [PMID: 17171479 DOI: 10.1007/s00268-006-0077-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
253 Kataria K, Verma GR, Malhotra A, Yadav R. Comparison of quality of life in patients undergoing transhiatal esophagectomy with or without chemotherapy. Saudi J Gastroenterol. 2012;18:195-200. [PMID: 22626799 DOI: 10.4103/1319-3767.96454] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
254 Cools-Lartigue J, Spicer J, Ferri LE. Current status of management of malignant disease: current management of esophageal cancer. J Gastrointest Surg 2015;19:964-72. [PMID: 25650163 DOI: 10.1007/s11605-014-2701-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
255 Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 2011;11:266. [PMID: 21702914 DOI: 10.1186/1471-2407-11-266] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
256 Chiu PW, Chan AC, Leung SF, Leong HT, Kwong KH, Li MK, Au-Yeung AC, Chung SC, Ng EK. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005;9:794-802. [PMID: 16187480 DOI: 10.1016/j.gassur.2005.05.005] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 7.1] [Reference Citation Analysis]
257 Kanda M, Shimizu D, Miyata K, Maeda O, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Ando M, Kuwatsuka Y, Murotani K, Nakayama G, Koike M, Ando Y, Ebata T, Kodera Y. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial. Contemp Clin Trials Commun 2021;24:100853. [PMID: 34820548 DOI: 10.1016/j.conctc.2021.100853] [Reference Citation Analysis]
258 Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70-75. [PMID: 14710209 DOI: 10.1038/sj.bjc.6601461] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 4.2] [Reference Citation Analysis]
259 Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol 2006;8:22-30. [PMID: 16632436 DOI: 10.1007/s12094-006-0091-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
260 Zhou J, Shen J, Seifer BJ, Jiang S, Wang J, Xiong H, Xie L, Wang L, Sui X. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget 2017;8:30477-94. [PMID: 27802185 DOI: 10.18632/oncotarget.12955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
261 Korn WM. Prevention and management of early esophageal cancer. Curr Treat Options Oncol. 2004;5:405-416. [PMID: 15341678 DOI: 10.1007/s11864-004-0030-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
262 Qiu B, Li J, Wang B, Wang Z, Liang Y, Cai P, Chen Z, Liu M, Fu J, Yang H, Liu H. Adjuvant Therapy for a Microscopically Incomplete Resection Margin after an Esophagectomy for Esophageal Squamous Cell Carcinoma. J Cancer 2017;8:249-57. [PMID: 28243329 DOI: 10.7150/jca.16409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
263 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
264 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
265 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
266 Subramanyeshwar RT, Raju KVVN, Patnaik SC, Saksena AR, Pratap RR, Rayani BK, Naik VM, Nusrath S. Minimally Invasive Esophagectomy the Standard of Care: Experience from a Tertiary Care Cancer Center from India. Indian J Surg Oncol 2021;12:335-49. [PMID: 34295078 DOI: 10.1007/s13193-021-01291-y] [Reference Citation Analysis]
267 Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, Uramoro H, Yasumoto K. Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient. Surg Today 2012;42:272-9. [PMID: 22234743 DOI: 10.1007/s00595-011-0083-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]